Ken Griffin Bridge Bio Pharma, Inc. Transaction History

Citadel Advisors LLC

$559 Billion
Q4 2024

A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Bridge Bio Pharma, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 383,200 shares of BBIO stock, worth $13.6 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

383,200

Previous 231,500 65.53%

Holding current value

$13.6 Million

Previous $5.89 Million 78.43%

% of portfolio

0.0%

Previous 0.0%

20 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 14, 2025	SELL	$22.35 - $29.5 $37.7 Million - $49.8 Million	-1,686,753 Reduced 57.33%	1,255,361 $34.4 Million
Q3 2024 Nov 14, 2024	BUY	$23.91 - $31.3 $18.8 Million - $24.6 Million	785,665 Added 36.43%	2,942,114 $74.9 Million
Q2 2024 Aug 14, 2024	BUY	$23.0 - $31.04 $29.3 Million - $39.5 Million	1,273,174 Added 144.14%	2,156,449 $54.6 Million
Q1 2024 May 15, 2024	BUY	$27.35 - $40.45 $5.99 Million - $8.86 Million	219,120 Added 32.99%	883,275 $27.3 Million
Q4 2023 Feb 14, 2024	BUY	$24.02 - $43.89 $2.29 Million - $4.19 Million	95,495 Added 16.79%	664,155 $26.8 Million
Q3 2023 Nov 14, 2023	BUY	$16.89 - $35.01 $2.62 Million - $5.43 Million	155,050 Added 37.49%	568,660 $15 Million
Q2 2023 Aug 14, 2023	BUY	$13.29 - $18.01 $1.69 Million - $2.29 Million	126,878 Added 44.25%	413,610 $7.11 Million
Q1 2023 May 15, 2023	SELL	$7.17 - $18.55 $18.6 Million - $48.1 Million	-2,590,456 Reduced 90.03%	286,732 $4.75 Million
Q4 2022 Feb 14, 2023	BUY	$6.74 - $11.52 $7.19 Million - $12.3 Million	1,066,176 Added 58.87%	2,877,188 $21.9 Million
Q3 2022 Nov 14, 2022	BUY	$7.94 - $12.36 $7.7 Million - $12 Million	969,218 Added 115.14%	1,811,012 $18 Million
Q2 2022 Aug 15, 2022	BUY	$5.21 - $12.14 $2.37 Million - $5.53 Million	455,732 Added 118.05%	841,794 $7.64 Million
Q1 2022 May 16, 2022	BUY	$7.34 - $17.16 $319,392 - $746,700	43,514 Added 12.7%	386,062 $3.92 Million
Q3 2021 Nov 15, 2021	SELL	$46.87 - $64.24 $3.28 Million - $4.5 Million	-70,030 Reduced 16.97%	342,548 $16.1 Million
Q2 2021 Aug 16, 2021	BUY	$46.47 - $63.93 $10.6 Million - $14.5 Million	227,093 Added 122.43%	412,578 $25.2 Million
Q1 2021 May 17, 2021	SELL	$55.47 - $72.35 $2.71 Million - $3.53 Million	-48,798 Reduced 20.83%	185,485 $11.4 Million
Q4 2020 Feb 16, 2021	BUY	$38.38 - $71.11 $4.63 Million - $8.58 Million	120,665 Added 106.2%	234,283 $16.7 Million
Q3 2020 Nov 16, 2020	BUY	$27.2 - $42.19 $1.81 Million - $2.81 Million	66,634 Added 141.82%	113,618 $4.26 Million
Q2 2020 Aug 14, 2020	BUY	$22.22 - $35.69 $324,767 - $521,645	14,616 Added 45.16%	46,984 $1.53 Million
Q1 2020 May 15, 2020	BUY	$16.11 - $36.23 $162,501 - $365,452	10,087 Added 45.27%	32,368 $939,000
Q2 2019 Aug 14, 2019	BUY	$26.97 - $27.55 $600,918 - $613,841	22,281 New	22,281 $601,000

Others Institutions Holding BBIO

# of Institutions

320

Shares Held

176M

Call Options Held

13M

Put Options Held

2.48M

View Full List

About BridgeBio Pharma, Inc.

Ticker BBIO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 148,246,000
Market Cap $5.26B
Description
BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases. The company has a pipeline of 30 development programs that include product candidates ranging from early discovery to late-stage development. Its products in development programs include AG10 and BBP-265, a small molecule stabili...

More about BBIO

Track Ken Griffin's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Account